PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
03. Mai 2024 11:00 ET
|
PharmAla Biotech
PharmAla launches new educational resource for prescribers of MDMA through the Special Access Program
PharmAla Announces Private Placement and Concurrent Debt Settlement
10. April 2024 16:30 ET
|
PharmAla Biotech
PharmAla Initiates $750,000 Private Placement with concurrent debt settlement, anticipated to close on April 17th 2024
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
05. April 2024 08:58 ET
|
PharmAla Biotech
PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
18. März 2024 08:55 ET
|
PharmAla Biotech
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme
World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment
09. November 2023 08:55 ET
|
PharmAla Biotech
PharmAla partners with Heroic Hearts Canada and the University of Calgary to launch the world's first observational rial into MDMA's real-world efficacy
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
07. November 2023 08:55 ET
|
PharmAla Biotech
PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments